The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent

Thrombosis Research

Volumn 128, Issue 4, 2011, Pages 352-357

  Gremmel, Thomas ^a   Steiner, Sabine ^a   Seidinger, Daniela ^a   Koppensteiner, Renate ^a   Panzer, Simon ^a   Kopp, Christoph W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

clopidogrel; Influencing factors; platelet reactivity

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; AGE DISTRIBUTION; AGED; ANGIOPLASTY; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BIOASSAY; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG DETERMINATION; FEMALE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIGHT TRANSMISSION AGGREGOMETRY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE ELECTRODE AGGREGOMETRY; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; SMOKING; STENT; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; TRANSIENT ISCHEMIC ATTACK;

ADENOSINE DIPHOSPHATE; ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; AUSTRIA; BIOLOGICAL MARKERS; BLOOD PLATELETS; CELL ADHESION MOLECULES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LINEAR MODELS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; RECEPTORS, PURINERGIC P2Y12; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; STENTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 80955179559     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.05.008     Document Type: Article

References (50)

1. P. Harrison, A.L. Frelinger III, M.I. Furman, and A.D. Michelson Measuring antiplatelet drug effects in the laboratory Thromb Res 120 2007 323 336 (Pubitemid 46879909)
2. P.A. Gurbel, K.P. Bliden, A. Etherington, and U.S. Tantry Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients Thromb Res 121 2007 107 115 (Pubitemid 350025991)
3. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913 (Pubitemid 36736631)
4. V.L. Serebruany, S.R. Steinhubl, P.B. Berger, A.I. Malinin, D.L. Bhatt, and E.J. Topol Variability in platelet responsiveness to clopidogrel among 544 individuals J Am Coll Cardiol 45 2005 246 251 (Pubitemid 40094733)
5. T. Geisler, H. Langer, M. Wydymus, K. Gohring, C. Zurn, and B. Bigalke Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation Eur Heart J 27 2006 2420 2425 (Pubitemid 44522148)
6. M.J. Price, S. Endemann, R.R. Gollapudi, R. Valencia, C.T. Stinis, and J.P. Levisay Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000 (Pubitemid 351844676)
7. D. Sibbing, S. Braun, T. Morath, J. Mehilli, W. Vogt, and A. Schomig Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 2009 849 856
8. L. Bonello, U.S. Tantry, R. Marcucci, R. Blindt, D.J. Angiolillo, and R. Becker Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
9. R. Marcucci, A.M. Gori, R. Paniccia, B. Giusti, S. Valente, and C. Giglioli Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 2009 237 242
10. P.A. Gurbel, K.P. Bliden, K. Guyer, P.W. Cho, K.A. Zaman, and R.P. Kreutz Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study J Am Coll Cardiol 46 2005 1820 1826 (Pubitemid 41579802)
11. S. Matetzky, B. Shenkman, V. Guetta, M. Shechter, R. Bienart, and I. Goldenberg Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
12. C. Frere, T. Cuisset, J. Quilici, L. Camoin, J. Carvajal, and P.E. Morange ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome Thromb Haemost 98 2007 838 843 (Pubitemid 47555077)
13. W. Hochholzer, D. Trenk, H.P. Bestehorn, B. Fischer, C.M. Valina, and M. Ferenc Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement J Am Coll Cardiol 48 2006 1742 1750 (Pubitemid 44648629)
14. J.M. Siller-Matula, G. Christ, I.M. Lang, G. Delle-Karth, K. Huber, and B. Jilma Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay J Thromb Haemost 8 2010 351 359
15. R. Blindt, K. Stellbrink, A. de Taeye, R. Muller, P. Kiefer, and E. Yagmur The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis Thromb Haemost 98 2007 1329 1334 (Pubitemid 350239106)
16. D. Sibbing, T. Morath, S. Braun, J. Stegherr, J. Mehilli, and W. Vogt Clopidogrel response status assessed with multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting Thromb Haemost 103 2010 151 159
17. N.J. Breet, J.W. van Werkum, H.J. Bouman, J.C. Kelder, H.J. Ruven, and E.T. Bal Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation JAMA 303 2010 754 762
18. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
19. T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, and N. Meneveau Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
20. F. Sofi, B. Giusti, R. Marcucci, A.M. Gori, R. Abbate, and G.F. Gensini Cytochrome P450 2C19(*)2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis Pharmacogenomics J 2010
21. W. Hochholzer, D. Trenk, M.F. Fromm, C.M. Valina, C. Stratz, and H.P. Bestehorn Impact of cytochrome P450 2 C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement J Am Coll Cardiol 55 2010 2427 2434
22. T. Gremmel, S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C.W. Kopp Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel J Thromb Haemost 8 2010 37 42
23. D. Sibbing, O. von Beckerath, A. Schomig, A. Kastrati, and N. von Beckerath Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention Am J Cardiol 100 2007 203 205 (Pubitemid 47041981)
24. N. Bonello-Palot, S. Armero, F. Paganelli, J. Mancini, A. De Labriolle, and C. Bonello Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention Am J Cardiol 104 2009 1511 1515
25. V. Serebruany, I. Pokov, W. Kuliczkowski, J. Chesebro, and J. Badimon Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease Thromb Haemost 100 2008 76 82 (Pubitemid 351948748)
26. M. Gilard, B. Arnaud, J.C. Cornily, G. Le Gal, K. Lacut, and G. Le Calvez Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study J Am Coll Cardiol 51 2008 256 260
27. T. Gremmel, S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C.W. Kopp Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition Heart 96 2010 186 189
28. W.C. Lau, L.A. Waskell, P.B. Watkins, C.J. Neer, K. Horowitz, and A.S. Hopp Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction Circulation 107 2003 32 37 (Pubitemid 36070929)
29. M. Lordkipanidze, C. Pharand, T.A. Nguyen, E. Schampaert, D.A. Palisaitis, and J.G. Diodati Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients Eur Heart J 29 2008 2877 2885
30. T. Gremmel, S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C.W. Kopp Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation Thromb Haemost 101 2009 333 339
31. R. Paniccia, E. Antonucci, A.M. Gori, R. Marcucci, C. Giglioli, and D. Antoniucci Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients J Thromb Haemost 5 2007 1839 1847 (Pubitemid 47288940)
32. H. Mani, K. Kirchmayr, C. Klaffling, M. Schindewolf, B. Luxembourg, and B. Linnemann Influence of blood collection techniques on platelet function Platelets 15 2004 315 318 (Pubitemid 39037133)
33. M. Cattaneo, A. Lecchi, M.L. Zighetti, and F. Lussana Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count Haematologica 92 2007 694 697 (Pubitemid 350144275)
34. B. Linnemann, J. Schwonberg, H. Mani, S. Prochnow, and E. Lindhoff-Last Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary J Thromb Haemost 6 2008 677 683 (Pubitemid 351404936)
35. D. Varon, R. Dardik, B. Shenkman, S. Kotev-Emeth, N. Farzame, and I. Tamarin A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions Thromb Res 85 1997 283 294 (Pubitemid 27143804)
36. B. Shenkman, S. Matetzky, P. Fefer, H. Hod, Y. Einav, and A. Lubetsky Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests Thromb Res 122 2008 336 345
37. J.M. Siller-Matula, S. Panzer, and B. Jilma Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay Platelets 19 2008 551 554
38. H.M. Judge, R.J. Buckland, A. Sugidachi, J.A. Jakubowski, and R.F. Storey Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function Thromb Haemost 103 2010 1210 1217
39. C. Bal Dit Sollier, N. Berge, B. Boval, M. Dubar, and L. Drouet Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel Thromb Haemost 104 2010 571 581
40. O. Toth, A. Calatzis, S. Penz, H. Losonczy, and W. Siess Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood Thromb Haemost 96 2006 781 788 (Pubitemid 44883819)
41. M.L. Kalb, L. Potura, G. Scharbert, and S.A. Kozek-Langenecker The effect of ex vivo anticoagulants on whole blood platelet aggregation Platelets 20 2009 7 11
42. T. Geisler, D. Grass, B. Bigalke, K. Stellos, T. Drosch, and K. Dietz The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score J Thromb Haemost 6 2008 54 61
43. J.M. Siller-Matula, I. Lang, G. Christ, and B. Jilma Calcium-channel blockers reduce the antiplatelet effect of clopidogrel J Am Coll Cardiol 52 2008 1557 1563
44. N. Sarafoff, L. Neumann, D. Morath, I. Bernlochner, J. Mehilli, and A. Schömig Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting Am Heart J 161 2011 605 610
45. K.P. Bliden, J. Dichiara, L. Lawal, A. Singla, M.J. Antonino, and B.A. Baker The association of cigarette smoking with enhanced platelet inhibition by clopidogrel J Am Coll Cardiol 52 2008 531 533
46. T. Gremmel, S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C.W. Kopp Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy Thromb Res 124 2009 588 591
47. M.J. Price, K.R. Nayak, C.M. Barker, D.E. Kandzari, and P.S. Teirstein Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention Am J Cardiol 103 2009 1339 1343
48. T. Geisler, C. Zurn, M. Paterok, K. Gohring-Frischholz, B. Bigalke, and K. Stellos Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy Eur Heart J 29 2008 1635 1643 (Pubitemid 351957543)
49. J.V. Mitsios, A.I. Papathanasiou, F.I. Rodis, M. Elisaf, J.A. Goudevenos, and A.D. Tselepis Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes Circulation 109 2004 1335 1338 (Pubitemid 38387816)
50. J.M. Siller-Matula, A.O. Spiel, I.M. Lang, G. Kreiner, G. Christ, and B. Jilma Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel Am Heart J 157 148 2009 e1 e5